Lilly reports tirzepatide trial results for obesity and pre-diabetes
At the 15mg dose, participants showed a sustained average weight loss of 22.9% during the three-year treatment. Credit: SB Arts Media / Shutterstock. Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy […]
